How good are we at preventing HIV? How do efficacy and effectiveness differ? We journey from oral pre-exposure prophylaxis (PrEP) to long-acting injectables, and then to the PURPOSE trials, which look at the use of long-acting lenacapavir as PrEP — a potential game-changer in the field of HIV.Listen to this latest episode of Beyond Journal Club, a collaboration between CoreIM and NEJM Group, where we put research into context, telling the story of how we arrived at the current standard of care, appreciating the clinical question of the trial at hand, and interpreting what the findings may mean for these patients.🔹 Sponsor: NEJM Fellowship Program, click here to learn more and/or apply!🔹 Transcript and Show NotesTimestamps:(02:25) | HIV PrEP Daily Truvada and Descovy (07:48) | On-Demand Prep(13:25) | Purpose Trials(20:56) | Discussion of Effectiveness to Efficacy Tags: CoreIM, Internal Medicine, Primary Care, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student, HIV Prevention, Infectious Disease Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Our Sponsors:* Check out Branch Basics: https://branchbasics.com/COREIM and use the code CoreIM for 15% * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Washington Red Raspberries: https://redrazz.orgAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related